These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

7179 related items for PubMed ID: 2905882

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Combined therapy of mice bearing a lymphokine-activated killer-resistant tumor with recombinant interleukin 2 and an antitumor monoclonal antibody capable of inducing antibody-dependent cellular cytotoxicity.
    Kawase I, Komuta K, Hara H, Inoue T, Hosoe S, Ikeda T, Shirasaka T, Yokota S, Tanio Y, Masuno T.
    Cancer Res; 1988 Mar 01; 48(5):1173-9. PubMed ID: 3257715
    [Abstract] [Full Text] [Related]

  • 3. Suppression of pulmonary tumour metastasis in mice by recombinant human interleukin-2: role of asialo GM1-positive cells.
    Hinuma S, Naruo K, Ootsu K, Houkan T, Shiho O, Tsukamoto K.
    Immunology; 1987 Feb 01; 60(2):173-9. PubMed ID: 3493209
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. In vivo effects of recombinant human interleukin 2 on antitumor and antiviral natural immunity in induced or natural murine immunodeficiency states.
    Butler LD, Browne CP, Layman NK, Riedl P, Tang J, Marder P, DeLong D, Manetta J, Bobbitt L, Strnad J.
    Cancer Res; 1988 Nov 01; 48(21):6081-9. PubMed ID: 3048654
    [Abstract] [Full Text] [Related]

  • 6. Antibody-dependent cellular cytotoxicity mediated by murine lymphocytes activated in recombinant interleukin 2.
    Shiloni E, Eisenthal A, Sachs D, Rosenberg SA.
    J Immunol; 1987 Mar 15; 138(6):1992-8. PubMed ID: 3493293
    [Abstract] [Full Text] [Related]

  • 7. Murine lymphokine-activated killer (LAK) cells: phenotypic characterization of the precursor and effector cells.
    Yang JC, Mulé JJ, Rosenberg SA.
    J Immunol; 1986 Jul 15; 137(2):715-22. PubMed ID: 2873187
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Effect of anti-B16 melanoma monoclonal antibody on established murine B16 melanoma liver metastases.
    Eisenthal A, Lafreniere R, Lefor AT, Rosenberg SA.
    Cancer Res; 1987 Jun 01; 47(11):2771-6. PubMed ID: 3494504
    [Abstract] [Full Text] [Related]

  • 12. IFN-gamma-inducing factor/IL-18 administration mediates IFN-gamma- and IL-12-independent antitumor effects.
    Osaki T, Péron JM, Cai Q, Okamura H, Robbins PD, Kurimoto M, Lotze MT, Tahara H.
    J Immunol; 1998 Feb 15; 160(4):1742-9. PubMed ID: 9469432
    [Abstract] [Full Text] [Related]

  • 13. Flow cytometric analysis reveals the presence of asialo GM1 on the surface membrane of alloimmune cytotoxic T lymphocytes.
    Suttles J, Schwarting GA, Stout RD.
    J Immunol; 1986 Mar 01; 136(5):1586-91. PubMed ID: 2936802
    [Abstract] [Full Text] [Related]

  • 14. Purification and target cell range of in vivo elicited blast natural killer cells.
    Biron CA, Pedersen KF, Welsh RM.
    J Immunol; 1986 Jul 15; 137(2):463-71. PubMed ID: 3722814
    [Abstract] [Full Text] [Related]

  • 15. Analysis of the murine lymphokine-activated killer (LAK) cell phenomenon: dissection of effectors and progenitors into NK- and T-like cells.
    Kalland T, Belfrage H, Bhiladvala P, Hedlund G.
    J Immunol; 1987 Jun 01; 138(11):3640-5. PubMed ID: 3495566
    [Abstract] [Full Text] [Related]

  • 16. Expansion of natural killer cells in mice transgenic for IgM antibody to ganglioside GD2: demonstration of prolonged survival after challenge with syngeneic tumor cells.
    Kawashima I, Yoshida Y, Taya C, Shitara H, Yonekawa H, Karasuyama H, Tada N, Furukawa K, Tai T.
    Int J Oncol; 2003 Aug 01; 23(2):381-8. PubMed ID: 12851687
    [Abstract] [Full Text] [Related]

  • 17. In vivo antitumor activity of multiple injections of recombinant interleukin 2, alone and in combination with three different types of recombinant interferon, on various syngeneic murine tumors.
    Iigo M, Sakurai M, Tamura T, Saijo N, Hoshi A.
    Cancer Res; 1988 Jan 15; 48(2):260-4. PubMed ID: 2446744
    [Abstract] [Full Text] [Related]

  • 18. Characteristics of murine non-specific killer cells induced in vivo by recombinant human interleukin-2.
    Hinuma S, Naruo K, Shiho O, Tsukamoto K.
    Immunology; 1986 Oct 15; 59(2):251-9. PubMed ID: 3490435
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Autocytotoxic activity of lymphokine-activated killer cells: characterization of effector cells and susceptible targets.
    Suzuki H, Ikemoto M, Kamitani T, Hoshino K, Yano S.
    Anticancer Res; 1989 Oct 15; 9(2):293-7. PubMed ID: 2568770
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 359.